https://scholars.lib.ntu.edu.tw/handle/123456789/631749| Title: | Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial | Authors: | Platzbecker, Uwe Wong, Raymond S M Verma, Amit Abboud, Camille Araujo, Sergio Chiou, Tzeon-Jye Feigert, John Yeh, Su-Peng Götze, Katharina Gorin, Norbert-Claude Greenberg, Peter Kambhampati, Suman Kim, Yoo-Jin Lee, Je-Hwan Lyons, Roger Ruggeri, Marco Santini, Valeria Cheng, Gregory Jang, Jun Ho Chen, Chien-Yuan Johnson, Brendan Bennett, John Mannino, Frank Kamel, Yasser Mostafa Stone, Nicole Dougherty, Souria Chan, Geoffrey Giagounidis, Aristoteles |
Issue Date: | Oct-2015 | Journal Volume: | 2 | Journal Issue: | 10 | Start page/Pages: | e417 | Source: | The Lancet. Haematology | Abstract: | Patients with myelodysplastic syndrome or acute myeloid leukaemia who are thrombocytopenic and unable to receive disease-modifying therapy have few treatment options. Platelet transfusions provide transient benefit and are limited by alloimmunisation. Eltrombopag, an oral thrombopoietin receptor agonist, increases platelet counts and has preclinical antileukaemic activity. We aimed to assess the safety and tolerability of eltrombopag for the treatment of thrombocytopenia in adult patients with advanced myelodysplastic syndrome, secondary acute myeloid leukaemia after myelodysplastic syndrome, or de-novo acute myeloid leukaemia. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/631749 | ISSN: | 23523026 | DOI: | 10.1016/S2352-3026(15)00149-0 |
| Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.